Neoplasms

Mouth and Tooth Diseases

Ear, Nose, and Throat Diseases

All Conditions

Rare Diseases

Nasopharyngeal Carcinoma

Carcinoma

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Nasopharyngeal Neoplasms

Pharyngeal Neoplasms

Otorhinolaryngologic Neoplasms

Head and Neck Neoplasms

Nasopharyngeal Diseases

Pharyngeal Diseases

Stomatognathic Diseases

Otorhinolaryngologic Diseases

Antineoplastic Agents

All Drugs and Chemicals

Gemcitabine

Paclitaxel

Albumin-Bound Paclitaxel

Capecitabine

Tislelizumab

Cisplatin

Tubulin Modulators

Antimitotic Agents

Antimetabolites

Antineoplastic Agents, Immunological

Patients diagnosed with wmNPC (more than five metastatic lesions) by histopathology are assigned to receive ISC following SC. Typically, SC(GP) was administered once every three weeks, with a maximum of six courses. Following this, ISC (TS1) was administered to extend the chemotherapy interval, once every 6-8 weeks, until widely progressive disease (WPD: defined as more than five progressive lesions), treatment intolerance, or patient refusal.

Paclitaxel protein-bound

a dose of 1-1.25 g/m2 twice daily in in 2 weeks for one cycle

Shaojun Lin, DR

This study aimed to investigate the value of a novel strategy of intermittent systematic chemotherapy (ISC) in widely metastatic nasopharyngeal carcinoma (wmNPC) patients who achieve objective response after systematic chemotherapy (SC).

Widely metastatic nasopharyngeal carcinoma (wmNPC) represented a particular subgroup of patients with the worst prognosis, of which palliative systematic chemotherapy(SC) was recommended as initial treatment, however, palliative systematic treatment was often required to be stopped due to the cumulative toxicities while stopping SC may lead to disease progression, a 'stop and go' approach, namely chemotherapy 'holidays', was a new strategy which may keep a good balance of benefit and risk. This study aimed to investigate the value of a novel strategy of intermittent systematic chemotherapy (ISC) in wmNPC patients who achieve objective response after SC.

Stop and go Strategy as First-line Treatment for Widely Metastatic Nasopharyngeal Carcinoma

Stop and go Strategy as First-line Treatment in Patients With Objective Response After Systematic Chemotherapy for Widely de Novo Metastatic Nasopharyngeal Carcinoma: A Phase II Trial

the time interval from the start of chemotherapy to the date of progression

the time interval from the start of chemotherapy to the date of wide progression

time from the date of the start of chemotherapy to death due to any cause

Fujian Cancer Hospital

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Uterine Cervical Neoplasms

Uterine Neoplasms

Genital Neoplasms, Female

Urogenital Neoplasms

Uterine Cervical Diseases

Uterine Diseases

Genital Diseases, Female

Genital Diseases

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Patients in group A don't receive neoadjuvant chemotherapy

Patients in group B receive neoadjuvant chemotherapy and achieve imaging response

Patients in group B receive neoadjuvant chemotherapy but don't achieve imaging response, and they accept concurrent chemoradiotherapy

Patients in group B receive neoadjuvant chemotherapy but don't achieve imaging response, and they accept radical hysterectomy

Two cycles of neoadjuvant chemotherapy (paclitaxel 175 mg/m2 and cisplatin 70 mg/m2, on day 1, once for three weeks).

Two cycles of neoadjuvant chemotherapy

First imaging evaluation consists of pelvic magnetic resonance imaging (MRI) and positron emission tomography (PET)

First imaging evaluation

Second imaging evaluation consists of pelvic magnetic resonance imaging

Second imaging evaluation

The third cycles of neoadjuvant chemotherapy (paclitaxel 175 mg/m2 and cisplatin 70 mg/m2, on day 1, once for three weeks).

The third cycles of neoadjuvant chemotherapy

Radiochemotherapy

Pathologic evaluation

Lei Li, M.D.

Lei Li, MD

This cohort study is to evaluate the role of neoadjuvant chemotherapy (NAC) in the treatment of locally advanced cervical cancer (LACC). Sixty patients with LACC (FIGO 2009 stage IB2 to IIB) will be enrolled. After informed consents, they would accept the imaging evaluation of pelvic magnetic resonance imaging (MRI) and positron emission tomography (PET). After excluding cases of distant metastasis, they will accept two cycles of NAC (paclitaxel 175 mg/m2 and cisplatin 70 mg/m2, on day 1, once for three weeks). Then a second MRI is performed to evaluate the imaging response. For patients achieving objective response, radical hysterectomy (RH, via laparoscopy or laparotomy) and an evaluation of pathologic response are performed. For patients without objective imaging response, the choice of concurrent chemoradiotherapy or radical hysterectomy will be discussed. After RH, adjuvant therapy will be given according to the RH pathologic results.

The primary objectives consist of (1) the objective imaging response after NAC; (2) the objective pathologic response after RH.

The secondary objectives consist of (1) disease-free survival and overall survival after various therapy modalities; (2) severe adverse effects of NAC; (3) the effects of NAC on the surgical outcomes.

patients diagnosed with locally advanced cervical cancer of stage IB2 to IIB (FIGO 2009 system)

NAC Followed by RH for the Treatment of LACC

Neoadjuvant Chemotherapy Followed by Radical Hysterectomy for the Treatment of Locally Advanced Cervical Cancer: A Prospective Cohort Study

Objective pathologic response for patients with radical hysterectomy

Objective imaging response for patients with neoadjuvant chemotherapy

Disease-free survival for patients with various therapy modalities

Overall survival for patients with various therapy modalities

Severe adverse events of neoadjuvant chemotherapy

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Stop and go Strategy as First-line Treatment for Widely Metastatic Nasopharyngeal Carcinoma	NCT06331845	Metastatic Naso... Intermittent Sy...	Gemcitabine Cisplatin Paclitaxel prot... Capecitabine Tislelizumab	18 Years - 70 Years	Fujian Cancer Hospital
NAC Followed by RH for the Treatment of LACC	NCT03963882	Neoadjuvant Che... Locally Advance... Radical Hystere... Objective Respo... Laparoscopy Laparotomy Concurrent Chem... Adjuvant Therap... Systematic Chem...	Two cycles of n... First imaging e... Second imaging ... The third cycle... RH Radiochemothera... Pathologic eval...	18 Years - 45 Years	Peking Union Medical College Hospital

Spots Global Cancer Trial Database for systematic chemotherapy